Skip to main content
. 2021 May 7;12:605766. doi: 10.3389/fimmu.2021.605766

Figure 4.

Figure 4

Cumulative incidences of relapse (CIR) and NRM. (A) Cumulative incidence of relapse: CAR T-cell group: 4-year CIR of 11.1% (95% CI: 10.3, 11.9%) vs. chemotherapy group: 12.8% (95% CI:12.6, 13.0%) (p=0.84). (B) Cumulative incidence of NRM: CAR T-cell group: 4-year NRM of 18.7% (95% CI:17.5, 19.9%) vs. chemotherapy group: 4-year NRM of 23.1% (95% CI:22.7, 23.5%); p=0.64.